A new Allied Market Research (AMR) report predicts that the global biosimilars market, which accounted for $1.3 billion in 2013, will generate $35 billion by 2020, driven in large part by the expiration of “most of the blockbuster patents” over the next four years—a new patent cliff. Because the EU’s stringent biosimilar regulations are considered the world’s benchmark and were the first to be drafted, the European market is ahead of other regions in developing these products. Still, the report notes, “Biosimilars developers have been using emerging markets with less intellectual property protection as their launch pad for established markets. With regulatory framework maturing in established markets, it will be easier for biosimilar manufacturers to quickly enter into such markets.” See FierceBiotech, July 22, 2014.